NAD+: Status, Evidence and Sellers

Every living cell contains NAD+, a coenzyme sitting at the middle of energy metabolism. It ferries electrons through the mitochondrial reactions that turn food into ATP, and it feeds the enzymes that mend DNA, control which genes are expressed, and handle cellular stress. Run short of it and none of that happens efficiently.

Levels drop considerably as people age; by middle age, tissue concentrations may sit around half of youthful ones. That decline is why the molecule attracts research attention as a possible driver of age-related metabolic trouble. Supplementing NAD+ itself orally does not work well, so most protocols use precursors (nicotinamide riboside or nicotinamide mononucleotide) or put NAD+ straight in by IV or injection.

People come to it for energy, focus, recovery and longevity generally, so set expectations accordingly. It is not a weight-loss drug, the human trial evidence is early, and the striking anti-aging results from animal models have not reproduced in large human trials. The biology is interesting, but the clinical proof in healthy adults is not there yet.

Two enzyme families consume it. Sirtuins, deacylases involved in silencing genes, repairing DNA and regulating metabolism, cannot work without it, so their activity falls as it falls. PARPs also consume it while repairing single-strand DNA breaks, which sets up an unpleasant loop: heavy DNA damage drains NAD+ faster, and the depletion then degrades the repair capacity that was drawing on it [1][2].

The oral precursors enter cells through their own transporter routes and get converted inside. Human studies confirm both lift levels in blood and tissue. Delivering NAD+ intravenously puts it into circulation directly and skips the gut entirely. No published human trial has tested whether that produces higher tissue levels, or better outcomes, than swallowing a precursor.

The bioavailability groundwork came in 2016, when a single dose of nicotinamide riboside was shown to raise whole-blood NAD+ metabolites in healthy men [3]. That confirmed an oral precursor can lift NAD+ in people. It was a pharmacokinetic study rather than an outcomes trial, and it validated the approach without saying anything about benefit.

Then the clinical endpoints arrived, and they were sobering. Healthy adults of middle age and older took part in a six-week randomized placebo-controlled crossover trial: NAD+ metabolites rose reliably, and blood pressure, arterial stiffness and resting metabolic rate did not budge against placebo [4]. A 12-week randomized trial in men with obesity found the same pattern: NAD+ up, insulin sensitivity and skeletal muscle mitochondrial function unchanged [7]. Both are clean null results, in the populations most people asking about this belong to.

The more encouraging signals come from narrower groups. In a 2019 study, supplementation enriched the NAD+ metabolome of skeletal muscle from older humans, alongside anti-inflammatory changes in gene expression, though functional performance did not improve significantly [5]. In postmenopausal women carrying prediabetes and extra weight, a 2021 trial found ten weeks of NMN at 250 mg daily improved insulin signaling in muscle, the most clinically specific human finding in this literature so far. Nobody's weight shifted, and the study was small [6].

Reviews synthesizing the animal and early human work land in the same place: boosting NAD+ extends healthspan across multiple animal models and blunts metabolic disease phenotypes there, and whether that carries to humans remains unresolved [1][2]. That earns grade B: the mechanism is plausible and the NAD+-raising effect in humans is consistent, but the downstream clinical benefit in healthy adults is not. No controlled human trial of IV NAD+ specifically has ever been published; its use rests on mechanism and clinical anecdote.

No dose of NAD+ or its precursors is approved as a treatment. The precursor doses that have been tested come from trials. Twelve older men took 1 g of nicotinamide riboside a day for 21 days in a placebo-controlled crossover trial [5], and forty obese men took 1,000 mg twice a day for 12 weeks, which was well tolerated but did not improve insulin sensitivity [7]. A 10-week trial of NMN in women with prediabetes is the main human study of that precursor [6].

For injected or IV NAD+ there is no published trial dose to report, and the session amounts clinics quote are not drawn from one, so this page does not repeat them. How long to continue is not established either: the precursor trials cited here ran from three to twelve weeks.

The oral precursors have been well tolerated in trials at up to 1,000 to 2,000 mg a day over weeks to months. Mild stomach effects such as nausea, loose stools and some flushing are the usual complaints and generally settle with a dose adjustment. No serious adverse event has been attributed to an oral precursor in any published human trial so far.

The injectable and IV forms are a different story on comfort: flushing, chest tightness, palpitations and nausea are frequently reported, especially when the infusion runs fast, and generally ease when it is slowed. Whether anything worse happens is unknown, because serious adverse events from IV NAD+ have never been systematically characterized in a large trial. Unknown here means unstudied, not established as safe. It is not FDA-approved as a drug. Avoid it in pregnancy and breastfeeding, and in anyone with active cancer, since one theory holds that upregulating this pathway may feed tumor metabolism in some cancers, a question still open. Cardiac conditions or significant metabolic disease warrant a physician's assessment first.